CHF 36.12
(0.94%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 3.58 Billion USD | 21.38% |
2022 | 2.95 Billion USD | 0.37% |
2021 | 2.94 Billion USD | -9.76% |
2020 | 3.26 Billion USD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 1.02 Billion USD | 5.51% |
2024 Q2 | 1.02 Billion USD | 0.0% |
2023 Q3 | 1.15 Billion USD | 32.15% |
2023 Q1 | 893.28 Million USD | 8.41% |
2023 FY | 3.58 Billion USD | 21.38% |
2023 Q2 | 873.97 Million USD | -2.16% |
2023 Q4 | 971.44 Million USD | -15.89% |
2022 Q1 | 714.75 Million USD | 0.0% |
2022 FY | 2.95 Billion USD | 0.37% |
2022 Q4 | 824 Million USD | 1.35% |
2022 Q3 | 813.03 Million USD | 10.11% |
2022 Q2 | 738.39 Million USD | 3.31% |
2021 FY | 2.94 Billion USD | -9.76% |
2020 FY | 3.26 Billion USD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Relief Therapeutics Holding AG | 114.94 Million CHF | -3019.447% |
Tecan Group AG | 254.49 Million CHF | -1308.856% |
Santhera Pharmaceuticals Holding AG | 31.33 Million CHF | -11342.553% |
Basilea Pharmaceutica AG | 111.63 Million CHF | -3111.828% |
Bachem Holding AG | 47.58 Million CHF | -7435.305% |
Siegfried Holding AG | 148.34 Million CHF | -2317.099% |
Molecular Partners AG | 20.3 Million CHF | -17560.94% |